Pfizer (PFE) reports positive Phase 2 results for its 25-valent pediatric pneumococcal vaccine candidate, showing robust immunogenicity, broader protection across 25 serotypes and enhanced serotype 3 responses versus PREVNAR 20
- The candidate was well tolerated with no safety concerns. Pfizer has initiated its Phase 3 pediatric programme and advanced its adult programme to a 35-valent candidate.
#PFIZER INC#PFE.US#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#PFE#US EQUITIES